Cyclin L1 (CCNL1) gene alterations in human head and neck squamous cell carcinoma.
We evaluated the expression and amplification of cyclin L1 (CCNL1) gene, a potential oncogene localised in the commonly amplified 3q25-28 region, in human head and neck squamous cell carcinomas (HNSCCs). Overexpression was observed in 55 out of 96 cases (57%) and amplification in nine out of 35 tumours (26%) with no relationships to the clinico-pathological parameters. The Cyclin L1 antibody we developed labels nuclear speckles in tumour cells compatible with a role for CCNL1 in RNA splicing.
Muller
D
D
Laboratoire de Biologie Tumorale, Centre de lutte contre le cancer Paul Strauss, 3 rue de la Porte de l'Hôpital, 67065 Strasbourg Cedex, France. btumorale@strasbourg.fnclcc.fr
Millon
R
R
Théobald
S
S
Hussenet
T
T
Wasylyk
B
B
du Manoir
S
S
Abecassis
J
J
D002294:Carcinoma, Squamous Cell / Q000235:genetics* / Q000473:pathology; D016022:Case-Control Studies; D016213:Cyclins / Q000096:biosynthesis* / Q000235:genetics*; D018450:Disease Progression; D005784:Gene Amplification; D020869:Gene Expression Profiling; D006258:Head and Neck Neoplasms / Q000235:genetics* / Q000473:pathology; D006801:Humans; D016133:Polymerase Chain Reaction; D012326:RNA Splicing
C468873:CCNL1 protein, human; D016213:Cyclins